{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:22:49Z","timestamp":1761844969291},"reference-count":33,"publisher":"Japanese Society of Internal Medicine","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018,12,15]]},"DOI":"10.2169\/internalmedicine.1060-18","type":"journal-article","created":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T17:45:58Z","timestamp":1544809558000},"page":"3551-3557","source":"Crossref","is-referenced-by-count":7,"title":["Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an &lt;i&gt;LDL Receptor&lt;\/i&gt; Mutation and a &lt;i&gt;PCSK9&lt;\/i&gt; V4I Mutation"],"prefix":"10.2169","volume":"57","author":[{"given":"Ryo","family":"Shirahama","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Arao City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takamichi","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Arao City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suguru","family":"Nagamatsu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Sueta","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Takashio","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadasuke","family":"Chitose","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Arao City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Fujisue","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Izumiya","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Kaikita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Hokimoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Hori","sequence":"additional","affiliation":[{"name":"Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Harada-Shiba","sequence":"additional","affiliation":[{"name":"Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Kajiwara","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Arao City Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisao","family":"Ogawa","sequence":"additional","affiliation":[{"name":"National Cerebral and Cardiovascular Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Tsujita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Bujo H, Takahashi K, Saito Y, et al. Clinical features of familial hypercholesterolemia in Japan in a database from 1996-1998 by the Research Committee of the Ministry of Health, Labour and Welfare of Japan. J Atheroscler Thromb 11: 146-151, 2004.","DOI":"10.5551\/jat.11.146"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation 126: 2408-2417, 2012.","DOI":"10.1161\/CIRCULATIONAHA.112.144055"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376: 1713-1722, 2017.","DOI":"10.1056\/NEJMoa1615664"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA 316: 2373-2384, 2016.","DOI":"10.1001\/jama.2016.16951"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ohta N, Hori M, Takahashi A, et al. Proprotein convertase subtilisin\/kexin 9 V4I variant with <i>LDLR<\/i> mutations modifies the phenotype of familial hypercholesterolemia. J Clin Lipidol 10: 547-555.e55, 2016.","DOI":"10.1016\/j.jacl.2015.12.024"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Harada-Shiba M, Arai H, Oikawa S, et al. Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb 19: 1043-1060, 2012.","DOI":"10.5551\/jat.14621"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur Heart J 34: 3478-3490, 2013.","DOI":"10.1093\/eurheartj\/eht273"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Genest J, Hegele RA, Bergeron J, et al. Canadian Cardiovascular Society position statement on familial hypercholesterolemia. Can J Cardiol 30: 1471-1481, 2014.","DOI":"10.1016\/j.cjca.2014.09.028"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Gidding SS, Champagne MA, de Ferranti SD, et al. The agenda for familial hypercholesterolemia. Circulation 132: 2167-2192, 2015.","DOI":"10.1161\/CIR.0000000000000297"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Group JJW. Guidelines for secondary prevention of myocardial infarction (JCS 2011). Circ J 77: 231-248, 2013.","DOI":"10.1253\/circj.CJ-66-0053"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Tsujita K, Sugiyama S, Sumida H, et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol 66: 495-507, 2015.","DOI":"10.1016\/j.jacc.2015.05.065"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Yamakawa-Kobayashi K, Kobayashi T, Saku K, Arakawa K, Hamaguchi H. Two novel frameshift mutations associated with the presence of direct repeats of the LDL receptor gene in familial hypercholesterolemia. Hum Genet 92: 331-335, 1993.","DOI":"10.1007\/BF01247329"},{"key":"13","unstructured":"13. ClinVar [Internet]. [cited 2018 Apr. 1]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/clinvar\/variation\/251954\/"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Friedman M, Byers SO, Rosenman RH. Resolution of aortic atherosclerotic infiltration in the rabbit by phosphatide infusion. Proc Soc Exp Biol Med 95: 586-588, 1957.","DOI":"10.3181\/00379727-95-23300"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Cholesterol Treatment Trialists&apos; (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376: 1670-1681, 2010.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Mabuchi H, Nohara A, Noguchi T, et al. Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan. Atherosclerosis 214: 404-407, 2011.","DOI":"10.1016\/j.atherosclerosis.2010.11.005"},{"key":"17","unstructured":"17. Japan Intractable Diseases Information Center [Internet]. [cited 2017 Oct. 1]. Available from: http:\/\/www.nanbyou.or.jp\/entry\/65 (in Japanese)."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Khachadurian A, Uthman S. Experiences with the homozygous cases of familial hypercholesterolemia. Ann Nutr Metab 15: 132-140, 1973.","DOI":"10.1159\/000175431"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Brown MS, Goldstein JL. Expression of the familial hypercholesterolemia gene in heterozygotes: mechanism for a dominant disorder in man. Science 185: 61-63, 1974.","DOI":"10.1126\/science.185.4145.61"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Vega G, Grundy S. <i>In vivo<\/i> evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia. J Clin Invest 78: 1410, 1986.","DOI":"10.1172\/JCI112729"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Abifadel M, Varret M, Rab\u00e8s JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34: 154-156, 2003.","DOI":"10.1038\/ng1161"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Harada-Shiba M, Tajima S, Yokoyama S, et al. Siblings with normal LDL receptor activity and severe hypercholesterolemia. Arterioscler Thromb 12: 1071-1078, 1992.","DOI":"10.1161\/01.ATV.12.9.1071"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Harada-Shiba M, Takagi A, Miyamoto Y, et al. Clinical features and genetic analysis of autosomal recessive hypercholesterolemia. J Clin Endocrinol Metab 88: 2541-2547, 2003.","DOI":"10.1210\/jc.2002-021487"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Garcia CK, Wilund K, Arca M, et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 292: 1394-1398, 2001.","DOI":"10.1126\/science.1060458"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Noguchi T, Katsuda S, Kawashiri MA, et al. The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation. Atherosclerosis 210: 166-172, 2010.","DOI":"10.1016\/j.atherosclerosis.2009.11.018"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Yu W, Nohara A, Higashikata T, Lu H, Inazu A, Mabuchi H. Molecular genetic analysis of familial hypercholesterolemia: spectrum and regional difference of LDL receptor gene mutations in Japanese population. Atherosclerosis 165: 335-342, 2002.","DOI":"10.1016\/S0021-9150(02)00249-6"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Fouchier SW, Kastelein JJ, Defesche JC. Update of the molecular basis of familial hypercholesterolemia in The Netherlands. Hum Mutat 26: 550-556, 2005.","DOI":"10.1002\/humu.20256"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Humphries SE, Whittall RA, Hubbart CS, et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet 43: 943-949, 2006.","DOI":"10.1136\/jmg.2006.038356"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Raal FJ, Hovingh GK, Blom D, et al. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol 5: 280-290, 2017.","DOI":"10.1016\/S2213-8587(17)30044-X"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Harada-Shiba M, Arai H, Okamura T, et al. Multicenter study to determine the diagnosis criteria of heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb 19: 1019-1026, 2012.","DOI":"10.5551\/jat.14159"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Khera AV, Won HH, Peloso GM, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol 67: 2578-2589, 2016.","DOI":"10.1016\/j.jacc.2016.03.520"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 365: 2078-2087, 2011.","DOI":"10.1056\/NEJMoa1110874"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Puri R, Nissen SE, Ballantyne CM, et al. Factors underlying regression of coronary atheroma with potent statin therapy. Eur Heart J 34: 1818-1825, 2013.","DOI":"10.1093\/eurheartj\/eht084"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/24\/57_1060-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T23:51:01Z","timestamp":1544831461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/24\/57_1060-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,15]]},"references-count":33,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1060-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,15]]}}}